Next‐generation sequencing‐based analysis to assess the pattern of relapse in patients with Philadelphia‐positive acute lymphoblastic leukemia. Issue 4 (9th September 2022)

• Record Type: Journal Article
• Authors: Ahn, Jae‐Sook; Kim, TaeHyung; Jung, Sung‐Hoon; Ahn, Seo‐Yeon; Song, Ga‐Young; Kim, Mihee; Yang, Deok‐Hwan; Lee, Je‐Jung; Kim, Mi Yeon; Moon, Joon Ho; Zhang, Zhaolei; Kim, Hyeoung‐Joon; Kim, Dennis Dong Hwan
• Is Part Of: EJHaem. Volume 3:Issue 4(2022)
• Page Start: 1145
• Page End: 1153
• Publication Date: 2022-09-09
• Subjects: NGS -- Philadelphia‐positive ALL -- relapse; Hematology -- Periodicals; 616.15
• DOI: 10.1002/jha2.514
• Languages: English
• ISSNs: 2688-6146

Abstract

Abstract: In this study, we performed serial monitoring using targeted DNA sequencing to identify genetic alterations in adults with Philadelphia‐positive acute lymphoblastic leukemia (Ph‐ALL). Deep sequencing was performed by targeting the coding regions of 45 genes with recurrent driver mutations and 1129 single nucleotide polymorphism sites. Of the 43 patients that we examined, at least one case of genetic alterations was detected in 38 (88%) of the 43 patients at diagnosis (somatic mutations in 10 patients [23%] and copy number aberrations [CNA] in 36 patients [84%]). The most frequently detected CNA lesions were in IKZF1 ( n = 25, 58%) and the most frequently mutated gene was SETD2 ( n = 5). At least one genetic abnormality (loss, gain, or persistence) was observed in all the samples obtained at relapse that were available for analysis ( n = 15), compared with the samples obtained at diagnosis (disappearance of any previously detected genetic alterations: 11 patients [73%]; new genetic abnormalities: nine patients [60%]; and persistent genetic abnormalities: eight patients [53%]]. The most frequently deleted lesions were in IKZF1 ( n = 9, 60%), and the most frequently mutated gene was ABL1 (eight patients, 53%). Our data indicate that leukemic progression may be associated with complex genetic alterations in Ph‐ALL during the course of treatment.